Molecular therapy for Myocardial Infarction: AP-1 (Activator protein-1) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 13/November/2018, 11.28 pm
Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as HNF4α, CADM2, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/November/2018,11.20 pm
November 13, 2018
Repurposing the anti-epileptic drug Valproic acid into an anti-diabetic (autoimmune) drug: Valproic acid (brand name: Convulex, Depakote, Epilim, Stavzor), a medication used to treat epilepsy and bipolar disorder and to prevent migraine headaches, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 13/november/2018, 11.59 pm
November 13, 2018What they say:
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature, by Prof Dimmler, Boon, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: AP-1 (Activator protein-1) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS
[easy_payment currency=”USD”]
From Significance of the study to Public Health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From Research Findings to Therapeutic Opportunity:
This study provides mechanistic insights into how AP-1 (Activator protein-1) may protect against myocardial infarction.
Figure 1. Mechanistic insights into how AP-1 (Activator protein-1) induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival
Figure 2. AP-1 (Activator protein-1) functions as a cardioprotective agent through induction of PNUTS
AP-1 (Activator protein-1), by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1). Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate aging; and (6) extend lifespan (fig 1). Together, this study suggests that pharmacological formulations encompassing “AP-1 or its activators, either alone or in combination with other drugs,” may be used to improve cardiac function after myocardial infarction (fig. 2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does AP-1 increase the expression of PNUTS/Telomerase?
Amount: $300#
# Research cooperation
For purchase and payment details, you may reach us at admin@genomediscovery.org
References:
Web:http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Molecular therapy for Myocardial Infarction: AP-1 (Activator protein-1) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of PNUTS, 13/November/2018, 11.28 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at admin@genomediscovery.org
